Plerixafor for mobilization of blood stem cells in autologous transplantation: an update

Bibliography

• Passweg JR, Baldomero H, Bregni M, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161-7
   PubMed Web of Science ®Google Scholar
• Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181-95
   PubMed Web of Science ®Google Scholar
• Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010;150:647-62
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua A, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yield for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009;84:335-7
   PubMed Web of Science ®Google Scholar
• Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic cells – definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-9
   PubMed Web of Science ®Google Scholar
• Jantunen E, Varmavuo V, Juutilainen A, et al. Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol 2012;91:1073-9
   PubMed Web of Science ®Google Scholar
• Sancho JM, Morgades M, Grifols JR, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34 (+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy 2012;14:823-9
   PubMed Web of Science ®Google Scholar
• de Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-64
   PubMed Web of Science ®Google Scholar
• de Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992;89:5286-90
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30
   PubMed Web of Science ®Google Scholar
• Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte colony –stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300
   PubMed Web of Science ®Google Scholar
• Hübel K, Liles WC, Broxmeyer H, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR antagonist. Support Cancer Ther 2004;1:165-72
   PubMedGoogle Scholar
• Broxmeyer H, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-18
   PubMed Web of Science ®Google Scholar
• Pusic I, DiPersio JF. Update on clinical experience with AMD3100, and SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic and progenitor cells. Curr Opin Hematol 2010;17:319-26
   PubMed Web of Science ®Google Scholar
• Keating GM. Plerixafor; a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011;71:1623-47
   PubMed Web of Science ®Google Scholar
• Dar A, Schajnovitz A, Lapid K, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 2011;25:1286-96
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 1998;10:179-85
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: implications for apheresis and graft composition. Transfus Apher Sci 2012;46:257-62
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39-47
   PubMed Web of Science ®Google Scholar
• Jantunen E. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther 2011;11:1241-8
   PubMed Web of Science ®Google Scholar
• Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff PJ, DiPersio JF, et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009;15:1578-86
   PubMed Web of Science ®Google Scholar
• Basak GW, Knopinska-Posluszny W, Matuszak M, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011;90:557-68
   PubMed Web of Science ®Google Scholar
• Duarte RF, Shaw BE, Marín P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011;46:52-8
   PubMed Web of Science ®Google Scholar
• Hübel K, Fresen MM, Apperley JF, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 2012;47:1046-50
   PubMed Web of Science ®Google Scholar
• Tanhehco YC, Vogl DT, Stadtmauer EA, et al. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion 2013;53:2314-26
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010;85:463-71
   PubMed Web of Science ®Google Scholar
• To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011;118:4530-40
   PubMed Web of Science ®Google Scholar
• Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120:413-23
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Penttilä K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917-22
   PubMed Web of Science ®Google Scholar
• Tempescul A, Ianotto JC, Hardy E, et al. Peripheral blood stem cell collection in elderly patients. Ann Hematol 2010;89:317-21
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-42
   PubMed Web of Science ®Google Scholar
• Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:718-23
   PubMed Web of Science ®Google Scholar
• Laszlo D, Galieni P, Raspadori D, et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000;37:157-61
   PubMed Web of Science ®Google Scholar
• Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant 2012;47:342-51
   PubMed Web of Science ®Google Scholar
• Attolico I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012;18:241-9
   PubMed Web of Science ®Google Scholar
• Lanza F, Lemoli RM, Olivieri A, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 2014;54:331-9
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff P, Stadtmauer EA, et al. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. Am J Hematol 2013;88:1017-23
   PubMed Web of Science ®Google Scholar
• Malard F, Kröger N, Gabriel IH, et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012;18:314-17
   PubMed Web of Science ®Google Scholar
• Basak GW, Jaksic O, Koristek Z, et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 2011;86:550-3
   PubMed Web of Science ®Google Scholar
• Jantunen E, Lemoli R. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012;52:906-14
   PubMed Web of Science ®Google Scholar
• D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011;46:356-63
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Mahlamäki E, et al. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011;86:299-304
   PubMed Web of Science ®Google Scholar
• Gopal AK, Karami M, Mayor J, et al. The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher 2012;27:81-7
   PubMed Web of Science ®Google Scholar
• Milone G, Tripepi G, Martino M, et al. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding “on demand” use of plerixafor. Blood Transfus 2013;11:94-101
   PubMed Web of Science ®Google Scholar
• Jantunen E, Varmavuo V, Juutilainen A, et al. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol 2012;91:1073-9
   PubMed Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011;17:729-36
   PubMed Web of Science ®Google Scholar
• Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011;51:2175-82
   PubMed Web of Science ®Google Scholar
• Kymes SM, Pusic I, Lambert DL, et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care 2012;18:33-41
   PubMed Web of Science ®Google Scholar
• Vishnu P, Roy V, Paulsen A, et al. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55-62
   PubMed Web of Science ®Google Scholar
• Aleš T, Veronika V, Zdeněk K, et al. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients. J Clin Apher 2013;28:395-403
   PubMed Web of Science ®Google Scholar
• Chaudhary L, Awan F, Cumpston A, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher 2013;28:359-67
   PubMed Web of Science ®Google Scholar
• Awan F, Kochuparambil ST, Falconer DE, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013;48:1279-84
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013;19:87-93
   PubMed Web of Science ®Google Scholar
• Menéndez P, Caballero MD, Prosper F, et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 2002;42:1159-72
   PubMed Web of Science ®Google Scholar
• Cesana C, Regazzi E, Garau D, et al. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens. Haematologica 1999;84:771-8
   PubMedGoogle Scholar
• Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992-1001
   PubMed Web of Science ®Google Scholar
• Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011;46:627-35
   PubMed Web of Science ®Google Scholar
• Miller JS, McCullar V, Punzel M, et al. Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Blood 1999;93:96-106
   PubMed Web of Science ®Google Scholar
• Rusten LS, Jacobsen SE, Kaalhus O, et al. Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells. Blood 1994;84:1473-81
   PubMed Web of Science ®Google Scholar
• Zubair AC, Kao G, Daley H, et al. CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 2006;8:399-407
   PubMed Web of Science ®Google Scholar
• Lanza F, Campioni D, Moretti S, et al. CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation. Exp Hematol 2001;29:1484-93
   PubMed Web of Science ®Google Scholar
• Taubert I, Saffrich R, Zepeda-Moreno A, et al. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 2011;13:459-66
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012;89:128-35
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Silvennoinen R, et al. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion 2013;53:1024-32
   PubMed Web of Science ®Google Scholar
• Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007;7:315-18
   PubMedGoogle Scholar
• Porrata LF, Gertz MA, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004;18:1085-92
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:291-8
   PubMed Web of Science ®Google Scholar
• Katipamula R, Porrata LF, Gastineau DA, et al. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target. Bone Marrow Transplant 2006;37:811-17
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003;44:997-1000
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008;14:807-16
   PubMed Web of Science ®Google Scholar
• Lundqvist A, Smith AL, Takahashi Y, et al. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol 2013;191:6241-9
   PubMed Web of Science ®Google Scholar
• Sheng L, Fu S, Hu Y, et al. Rapid mobilization of fully functional natural killer cells into blood by AMD3100. Transfusion 2013;53:2108-9; letter
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion 2012;52:1785-91
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Ho AD, Hanrahan J, et al. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011;17:943-55
   PubMed Web of Science ®Google Scholar
• Moreb JS, Salmasinia D, Hsu J, et al. Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients. Adv Hematol 2011;2011:517561
   PubMedGoogle Scholar
• Alexander ET, Towery JA, Miller AN, et al. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion 2011;51:1995-2000
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Rimpiläinen J, Kuitunen H, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients. Transfusion 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Josefsen D, Hetland G, Floisand Y, et al. The use of plerixafor in hard-to-mobilize lymphoma and multiple myeloma patients not only provide sufficient numbers of pbpcs to proceed to high dose therapy, but also have a positive impact on survival [abstract]. Blood 2013;122:5517
   Google Scholar
• Garfall AL, Dougherty A, Vogl DT, et al. Stem cell mobilization with plerixafor + G-CSF in comparison to cyclophosphamide + G-CSF and time-to-progression after autologous stem cell transplantation for multiple myeloma [abstract]. Blood 2013;122:3354
   Google Scholar
• Fruehauf S, Ehninger G, Hübel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010;45:269-75
   PubMed Web of Science ®Google Scholar
• Deol A, Abrams J, Masood A, et al. Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplant 2013;48:1112-16
   Google Scholar
• Khan RZ, Rosenbaum ER, Boota MM, et al. Risk of myelodysplastic syndrome (MDS) after hematopoietic progenitor cell collection using plerixafor [abstract]. Blood 2013;122:4650
   Google Scholar
• Morris C, Sureda A, van Biezen A, et al. The EMA-directed plerixafor safety survey: the EBMT CALM study [abstract]. Bone Marrow Transplant 2011;46(Suppl 1):S32
   Google Scholar
• Jantunen E, Ropponen A, Siitonen T, et al. Graft and outcome in autologous stem cell transplantation: a prospective GOA-study [abstract]. Bone Marrow Transplant 2013;48(Suppl 2):S532
   Google Scholar
• Kumar SK, Mikhael J, Laplant B, et al. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplant 2014;49:201-5
   PubMed Web of Science ®Google Scholar
• Cooper DL, Pratt K, Baker J, et al. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clin Lymphoma Myeloma Leuk 2011;11:267-72
   PubMed Web of Science ®Google Scholar
• Harvey RD, Kaufman JL, Johnson HR, et al. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biol Blood Marrow Transplant 2013;19:1393-5
   PubMed Web of Science ®Google Scholar
• Shi PA, Isola LM, Miller L. Prospective study of mobilization kinetics up to 18 hours after late afternoon dosing of plerixafor [abstract]. Blood 2013;122:4510
   Google Scholar
• Lefrère F, Mauge L, Réa D, et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. Transfusion 2013;53:564-9
   PubMed Web of Science ®Google Scholar
• Peled A, Abraham M, Avivi I, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 2014;20:469-79
   PubMed Web of Science ®Google Scholar
• Rettig MP, Ghobadi A, Holt M, et al. ALT-1188: a new CXCR4 antagonist in development for mobilization of HSPCs [abstract]. Blood 2013;122:891
   Web of Science ®Google Scholar
• Karpova D, Dauber K, Spohn G, et al. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 2013;27:2322-31
   PubMed Web of Science ®Google Scholar
• He S, Chu J, Vasu S, et al. FLT3 and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcomes. Biol Blood Marrow Transplant 2013. [Epub ahead of print]
   Google Scholar
• Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-9
   PubMed Web of Science ®Google Scholar
• Sinha S, Gastineau D, Micallef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011;46:943-9
   PubMed Web of Science ®Google Scholar
• Chen AI, Bains T, Murray S, et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 2012;47:1526-9
   PubMed Web of Science ®Google Scholar
• Abhyankar S, DeJarnette S, Aljitawi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012;47:483-7
   PubMed Web of Science ®Google Scholar
• Ozsan GH, Micallef IN, Dispenzieri A, et al. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. Am J Hematol 2012;87:1-4
   PubMed Web of Science ®Google Scholar
• Hay AE, Lawrie A, Robinson N, et al. A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly. J Clin Apher 2013;28:378-80
   PubMed Web of Science ®Google Scholar
• Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leuk Lymphoma 2014;55:331-6
   PubMed Web of Science ®Google Scholar